SNT Shares Syntara Limited
WATCH ASX · ASXDeep valuation discount offers asymmetric upside if clinical execution improves.
Signal breakdown
- ▸Large analyst valuation gap despite recent weakness.
- ▾Below 50-day MA (-23.6%)
- ▾Near 52-week low (0% of range)
Is SNT a buy right now?
Trend: SNT is trading below the 50-day average (-10.00%), RSI 39 — neutral momentum, with a 3-month return of -18.18%.
Valuation & quality: Syntara Limited trades on forward P/E -6.0, PEG 2.49, price-to-book 2.25; fundamentals show net margin -129.8%, return on equity -59.7%, revenue growth -13.3% year on year.
Analyst consensus: 2 analysts have a mean 12-month price target of A$0.10 (+483.3% vs the last close; range A$0.06 – A$0.15), consensus rating “none”.
Our screen: WATCH (score 0) — Deep valuation discount offers asymmetric upside if clinical execution improves.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -33.30% | +50.00% | +0.00% | -33.30% | +0.00% |
Fundamentals
Analyst price target
Technical signals
About Syntara Limited
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.